Top Markets
Coin of the day
Gongwin Biopharm Holdings Co., Ltd. Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd.

6617
Rang in Aktien #13752
Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical... Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concluded Phase III clinical trials for lung cancer. Additionally, PTS100 is currently progressing through Phase II clinical trials for liver cancer, while PTS-02 is being developed to address adenoid cystic carcinoma, and PTS500 targets malignant pleural effusion. Established in 2014, Gongwin Biopharm is headquartered in Taipei, Taiwan.
Aktienkurs
$3.83
Marktkapitalisierung
$464.45M
Veränderung (1 Tag)
-1.63%
Veränderung (1 Jahr)
17.17%
Land
TW
Handel Gongwin Biopharm Holdings Co., Ltd. (6617)

Kategorie

Kursverlauf für Gongwin Biopharm Holdings Co., Ltd. (6617)
Höchster Schlusskurs: $3.43 am 2026-08-01

Niedrigster Schlusskurs: $2.71 am 2017-02-01
Kursverlauf der Aktie von Gongwin Biopharm Holdings Co., Ltd. von 2017 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -1.11%
2025 -19.11%
2024 -45.63%
2023 -41.34%
2022 10.61%
2021 7.85%
2020 318.74%
2019 -1.25%
2018 12.21%
2017 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$885.01 28.89%
US
$323.36 10.89%
US
$234.55 57.65%
US
$187.22 0.00%
US
$1.90 -7.01%
AU